Your email has been successfully added to our mailing list.

×
0 0 0 0 0.47741935483871 1.86451612903226 1.97064516129032 1.87090322580645
Stock impact report

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Salarius Pharmaceuticals, Inc. (SLRX) 
Company Research Source: GlobeNewswire
Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and Decoy T Read more
Impact Snapshot
Event Time:
SLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Created with Highstock 5.0.1230sec1m5m10m30m60m90m120m0.00%50.00%100.00%150.00%200.00%250.00%
Opt-in for SLRX alerts
Opt-in for
SLRX alerts

from News Quantified
Opt-in for
SLRX alerts

from News Quantified